Matthew Robinson
`
`Microbiotica, Chesterford Research Park,
` mrobinson@microbiotica.com
`Cambridge, CB10 1XL. UK
` 01223 869309
`
`
`Profile
`
`
`Extensive experience in biological and biomedical research (12 years in academia and 14 years
`in
`industry)
`including fundamental basic mechanistic studies, human disease biology,
`microbiome science, all stages of pre-clinical drug discovery and clinical development. Strategic
`and executive roles in pharma and biotech.
`
`
`Research Experience
`
`teams
`
`
`2019-present:
`Microbiotica, Cambridge, UK
`SVP Research (2022- ); VP of Translational Biology (2109-2022)
`Position:
`Roles and Responsibilities:
`
`
`Member of company executive team
`
`Lead microbiome platform, discovery science and discovery
`(Translational Biology, Discovery Microbiology and Bioinformatics)
`Established Translational Biology Group (in vitro and in vivo teams)
`
`
`
`2017-2019:
`MedImmune/AstraZeneca, Cambridge, UK
`Associated Director
`Position:
`Oncology- Research
`Department:
`Roles and Responsibilities:
`
`
`Led a team of 9 preclinical research scientists.
`
`Led preclinical immuno-oncology projects.
`
`Research representative for Oleclumab clinical development team
`
`Chair of strategic team focused on novel T cell targeted therapies in oncology.
`
`Laboratory design and transition planning for move to new site
`
`2008-2017:
`MedImmune, Cambridge, UK
`Senior Scientist (2012-2017); Scientist II (2008-2012)
`Position:
`Respiratory, Inflammation and Autoimmunity- Research
`Department:
`Roles and Responsibilities:
`
`
`Team Leader in Preclinical Research
`
`Led preclinical projects in IBD, COPD, asthma and autoimmunity.
`
`Co-chair of cross-functional IBD strategy team
`
`Member of Clinical Development Teams for Brazikumab in Ph2a to Ph2b for
`Crohn’s disease and Abrilumab Ph2b for Crohn’s disease and ulcerative colitis.
`
`
`
`

`

`2005-2008:
`Position:
`Area of Interest:
`Achievements:
`
`
`2001-2005:
`Position:
`Area of Interest:
`Achievements:
`
`
`1996-2001:
`
`Position:
`Area of Interest:
`Achievements:
`
`
`
`
`
`1996-2000:
`
`
`1992-1996:
`
`
`Cancer Research UK LRI (now part of Francis Crick Institute), London, UK.
`Postdoctoral Research Fellow
`Innate immune receptors that recognise fungi.
`Identification of the pattern recognition receptors expressed by dendritic cells
`that engage fungi, one of which is novel. Elucidation of the signalling pathways
`triggered by these fungal receptors. Analysis of the resultant cell activation,
`cytokine release and adaptive
`immune response by assessment of T
`lymphocyte differentiation.
`
`National Institute for Medical Research, London, UK.
`Postdoctoral Research Fellow
`Macrophage cell signalling in response to inflammatory stimuli.
`Elucidation of two mechanisms by which LPS activates the MAP3-kinase TPL-2,
`namely degradation of an
`inhibitor and
`identification of a regulatory
`phosphorylation site. Determination of how this regulation contributes to
`macrophage activation and induction of TNF.
`
`Imperial Cancer Research Fund (now part of Francis Crick Institute), London,
`UK.
`Post Graduate Student and Research Fellow
`Neutrophil S100 proteins associated with inflammation.
`Cloning and characterising a novel family member. Dissection of the
`mechanisms by which these molecules modulate cell adhesion in vitro.
`
`Education
`
`PhD in Immunology at Imperial Cancer Research Fund (Awarded by University
`College London)
`
`BSc hon from the University of Bath, UK. Upper Second-class honours
`
`
`
`
`Publications
`
`
`Publications
`
`Villemin C, Six A, Neville BA, Lawley TD, Robinson MJ, Bakdash G. 2023
`The heightened importance of the microbiome in cancer immunotherapy.
`Trends Immunol. 44:44-59
`
`Thompson NA, Stewart GD, Welsh SJ, Doherty GJ, Robinson MJ, …..Corrie PG. 2022
`The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer
`patients receiving immune checkpoint inhibitor therapy.
`BMC Cancer. 22:99
`
`

`

`
`Hair J, Robinson MJ, Wilkinson RW, Dovedi SJ. 2022
`Deep phenotyping of surface stimulatory and inhibitory co-receptors on cancer-resident T and NK cells reveals cell
`subsets within the tumor-reactive CTL population that are uniquely defined by NKG2A expression.
`SLAS Discov. 27:95-106.
`
`Corkill DJ, Hunt AN, Hinrichs MJ, White N, Rebelatto M, Roskos L, Nys J, Scott A, Robinson MJ, Ryan P, Postle AD,
`Sleeman MA. 2021
`Chronic pharmacological antagonism of the GM-CSF receptor in mice does not replicate the pulmonary alveolar
`proteinosis phenotype but does alter lung surfactant turnover.
`Clin Sci (Lond). 135:2559-2573
`
`Sitnikova SI, Munnings-Tomes S, Galvani E, Kentner S, Mulgrew K, Rands C, España Agustí J, Zhang T, Ilieva KM,
`Rosignoli G, Ghadially H, Robinson MJ, Slidel T, Wilkinson RW, Dovedi SJ. 2021
`Novel non-terminal tumor sampling procedure using fine needle aspiration supports immuno-oncology biomarker
`discovery in preclinical mouse models.
`J Immunother Cancer 9:e002894
`
`Foster WS, Grime CJ, Tan HL, Williams GS, Robinson MJ, Carlesso G, Saglani S, Lloyd CM and Harker JA. 2020
`Enhanced frequency and function of follicular T cells in the tonsils of house dust mite-sensitized children.
`Allergy 75:1240
`
`Belchamber KB, Singh R, Whyte MK, Dockrell DH, Kilty I, Robinson MJ, Wedzicha JA, Barnes PJ, Donnelly LE,
`COPDMAP consortium. 2019
`Defective bacterial phagocytosis is associated with dysfunctional mitochondria in COPD macrophages.
`Eur. Respir. J. 10:54
`
`Martinez-Lopez M, Iborra S, Conde-Garrosa R, Mastrangelo A, Danne C, Mann ER, Reid DM, Gaboriau-Routhiau V,
`Chaparro M, Lorenzon MP, Minnerup L, Saz-Leal P, Slack E, Kemp B, Gisbert JP, Dzionek A, Robinson MJ, Ruperez
`FJ, Cerf-Bensussan N, Brown GD, Bernardo D, LeibundGut-Landmann S and Sancho D. 2019
`Microbiota sensing by Mincle-Syk axis in dendritic cells regulates IL-17 and IL-22 and promotes intestinal immune
`barrier.
`Immunity 50:446
`
`Spooner W, McLaren W, Slidel T, Finch DK, Butler R, Campbell J, Eghobamien L, Rider D, Kiefer CM, Robinson MJ,
`Hardman C, Cunningham F, Vaughan T, Flicek P, Huntington CC. 2018
`Haplosaurus computes protein haplotypes for use in precision drug design
`Nat. Commun. 9:4128
`
`Cook AD, Robinson MJ, Sleeman MA and Hamilton JA. 2016
`GM-CSF drives monocyte differentiation into inflammatory dendritic cells indirectly
`Arthritis Res Ther 18:287
`
`Iborra S, Martinez-Lopez M, Izquierdo HM, Abram CL, Conde-Garrosa R, Campos-Martin Y, Reguera R, Kemp B,
`Robinson MJ, Soto M, Lowell CA and Sancho D. 2016
`Leishmania targets a novel Mincle/SHP-1 axis on dendritic cells to subvert adaptive immunity to infection.
`Immunity 45:788-801
`
`Campbell JI, Nys J, Eghobamien L, Robinson MJ* and Sleeman MA*. 2016
`Pulmonary Pharmacodynamics of an anti-GM-CSFRα antibody enables systemic dosing that spares the lung
`compartment.
`MAbs Journal 8:1398-1406
`
`
`
`

`

`Percival-Alwyn JL, England E, Kemp B, Rapley L, Davis NH, McCarthy GR, Majithiya JB, Corkill DJ, Welsted S, Minton
`K, Cohen ES, Robinson MJ, Dobson C, Wilkinson TC, Vaughan TJ, Groves MA, Tigue NJ 2015
`Generation of potent mouse monoclonal antibodies to self-proteins using T-cell epitope ”tags”.
`MAbs Journal 7:129-37
`
`Clarke DL, Davis NHE, Campion CL, Foster ML, Heasman SC, Lewis AR, Anderson IK, Corkill DJ, Sleeman MA, May
`RD, Robinson MJ. 2014
`Dectin-2 sensing of house Dust Mite is critical for the initiation of airway inflammation.
`Mucosal Immunol. 7:558-67.
`
`Mouraor-Sa D, Robinson MJ, Zelenay S, Sancho D, Chakravarty P, Larsen R, Plantinga M, Van Rooijen N, Soares
`MP, Lambrecht B, Reis e Sousa. 2011
`CLEC-2 signalling via Syk in myeloid cells can regulate inflammatory responses
`Eur. J. Immunol.41:3040-53.
`
`Rosas M, Osorio F, Robinson MJ, Davies LC, Dierkes N, Jones SA, Reis e Sousa C, Taylor PR
`Hoxb8 conditionally-immortalised macrophage lines model inflammatory monocyte cells with important similarity
`to dendritic cells. 2010
`Eur. J. Immunol. 41:356-65.
`
`Robinson MJ*, Osorio F*, Rosas M, Schweighoffer E, Gros O, Verbeek JS, Ruland J, Tybulewicz V, Brown GD, Moita
`LF, Taylor PR, Reis e Sousa C. 2009
`Dectin-2 is a Syk-coupled pattern recognition receptor crucial for Th17 responses to fungal infection.
`J. Ex. Med. 206:2037-51
`
`Robinson MJ*, Beinke S*, Kouroumalis A, Tsichlis PN, Ley SC. 2007
`Phosphorylation of TPL-2 on serine 400 is essential for lipopolysaccharide activation of ERK in macrophages.
`Mo-. Cell. Biol. 27:7355-64
`
`Slack EC, Robinson MJ, Hernanz-Falcón P, Brown GD, Schweighoffer E, Tybulewicz VL, Reis e Sousa C. 2007
`Syk-dependent ERK activation regulates IL-2 and IL-10 production by DC stimulated with zymosan.
`Eur. J. Immunol. 37:1600-12.
`
`LeibundGut-Landmann S, Gross O, Robinson MJ, Osorio F, Slack EC, Tsoni SV, Schweighoffer E, Tybulewicz V,
`Brown GD, Ruland J, Reis e Sousa C. 2007
`Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce IL 17.
`Nat. Immunol. 8:630-8.
`
`Robinson MJ, Sancho D, Slack E, LeibundGut-Landmann S, Reis e Sousa C. 2007
`Myeloid C-type lectins in innate immunity. (Review)
`Nat. Immunol. 7:1258-65.
`
`Beinke S*, Robinson MJ*, Hugunin M, Ley SC. 2004
`Lipopolysaccharide activation of the TPL-2/MEK/extracellular signal-regulated kinase mitogen-activated protein
`kinase cascade is regulated by IκB kinase-induced proteolysis of NF-κB1 p105.
`Mol. Cell. Biol. 24:9658-67
`
`Robinson MJ, Tessier P, Poulsom R, Hogg N. 2002
`The S100 family heterodimer, MRP-8/14, binds with high affinity to heparin and heparan sulfate
`glycosaminoglycans on endothelial cells.
`J. Biol. Chem. 277:3658-65
`
`Hobbs JA, May R, Tanousis K, McNeill E, Mathies M, Gebhardt C, Henderson R, Robinson MJ, Hogg N. 2003
`Myeloid cell function in MRP-14 (S100A9) null mice.
`Mol. Cell. Biol. 23:2564-76
`
`

`

`
`Robinson MJ, Hogg N
`A comparison of human S100A12 with MRP-14 (S100A9). 2000
`Biochem. Biophys. Res. Commun. 275:865-70
`
`Gubareva LV, Robinson MJ, Bethell RC, Webster RG. 1997
`Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-
`guanidino-Neu5Ac2en.
`J. Virol. 71:3385-90
`
`Cusdin FS, Robinson MJ, Holman GD, Hough DW, Danson MJ. 1996
`Characterisation of glucose transport in the hyperthermophilic Archaeon Sulfolobus solfataricus.
`FEBS Lett. 387:193-5
`
` *
`
` These authors contributed equally
`
`
`Patents and patent applications as named inventor
`
`
`
`Country
`Name
`
`/ National
` Filing
`Phase Entry No.
`
`
`Filing/National
`Phase
`Entry
`Date
`04 Oct 2021
`19 May 2021
`19 May 2021
`21 Nov 2022
`15 Dec 2022
`15 Dec 2022
`15 Nov 2022
`09 Dec 2022
`19 May 2021
`
`WIPO
`Canada
`Canada
`China
`EPO
`EPO
`Israel
`India
`Republic of
`Korea
`USA
`
`USA
`USA
`
`WIPO
`WIPO
`
`
`
`PCT/GB2021/052558
`3178513
`3178982
`202180036768.2
`21731263.6
`21731264.4
`IL298231A
`202247071099
`1020227043932
`
`17/324,898
`
`17/324,899
`17/834,584
`
`19 May 2021
`
`19 May 2021
`07 Jun 2022
`
`PCT/GB2021/051206
`PCT/GB2021/051208
`
`19 May 2021
`19 May 2021
`
` Publication
`Number
`
`Publication
`Date
`
` Patent
`Number
`
` Grant Date
`
` Status
`
`WO2022/069907
`
`
`115667555
`4153786
`4153787
`
`202247071099
`
`
`US-2021-
`0275602A1
`2021-0341458
`US-2023-
`0090495A1
`WO2021/234380
`WO2021/234382
`
`07 Apr 2022
`25 Nov 2021
`25 Nov 2021
`31 Jan 2023
`29 Mar 2023
`29 Mar 2023
`1 Jan 2023
`06 Jan 2023
`26 Jan 2023
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Nationalised
`Pending
`Pending
`Pending
`Pending
`Pending
`
`Pending
`Pending
`
`09 Sep 2021
`
`11,439,671
`
`04 Nov 2021
`23 Mar 2023
`
`11,376,285
`
`
`Sep
`
`13
`2022
`05 Jul 2022
`
`
`Granted
`
`Granted
`Pending
`
`25 Nov 2021
`25 Nov 2021
`
`
`
`
`
`
`
`Nationalised
`Nationalised
`
`